The Ugly Cost Of Developing New Drugs -- Can We Make It Prettier?
For example, Chelsea Therapeutics received approval for Northera, a drug for neurogenic orthostatic hypotension, in 2014. The company, which was founded in 2002, is public and discloses its R&D spending. Since its creation, it adds up to $172 million.
Forbes - Thu, 20 Nov 2014 08:16

Dealing With Dementia: A Son Tells His Story
Just before diagnosis, she developed orthostatic hypotension. Her blood pressure would plunge, causing her to fall—once into the family Christmas tree—or pass out. The brain-cell damage caused fewer memory problems than Alzheimer's, which allowed ...
The Root - Tue, 11 Nov 2014 00:03

Purdue Pharma L.P. Receives FDA Approval for Hysingla™ ER (hydrocodone ...
Hysingla ER may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients. Monitor patients during dose initiation or titration. In patients with circulatory shock, Hysingla ER may cause vasodilation that can ...
SYS-CON Media (press release) - Thu, 20 Nov 2014 11:18

FDA Clears Droxidopa for Neurogenic Orthostatic Hypotension
The US Food and Drug Administration (FDA) today approved droxidopa (Northera, Chelsea Therapeutics) for the treatment of neurogenic orthostatic hypotension (NOH) that is associated with Parkinson's disease, multiple-system atrophy, and pure autonomic ...
Medscape - Tue, 18 Feb 2014 15:34

FDA approves treatment for neurogenic orthostatic hypotension
ModernMedicine - Thu, 20 Feb 2014 07:38

First Neurogenic Orthostatic Hypotension Drug OK'd in Two Decades
Monthly Prescribing Reference - Wed, 19 Feb 2014 06:26

FDA approves Northera for neurogenic orthostatic hypotension
The Pharma Letter - Wed, 19 Feb 2014 01:52

FDA approves Northera to treat neurogenic orthostatic hypotension
Healio - Wed, 19 Feb 2014 06:48

Chelsea shares jump 35% after hours on hypotension drug approval
MarketWatch (blog) - Tue, 18 Feb 2014 16:02

First Neurogenic Orthostatic Hypotension Drug Launched
Lundbeck announced the availability of Northera (droxidopa) capsules for the treatment of orthostatic dizziness and lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (eg, ...
Monthly Prescribing Reference - Tue, 02 Sep 2014 08:11

Lundbeck Announces Availability of NORTHERA™ (droxidopa) Capsules in the ...
Business Wire (press release) - Tue, 02 Sep 2014 06:41

Lundbeck launches Northera in USA
The Pharma Letter - Tue, 02 Sep 2014 08:45

Case Studies (November 2014)
Consequently, if JD attempts to stop smoking, regardless of pharmacologic or support group assistance, his serum levels of olanzapine may increase, putting him at greater risk for adverse effects, including orthostatic hypotension, dizziness ...
Pharmacy Times - Wed, 12 Nov 2014 13:02

Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the ...
Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects: SAPHRIS may induce orthostatic hypotension and syncope. SAPHRIS should be used with caution in patients with cardiovascular disease, cerebrovascular disease, or conditions which ...
SYS-CON Media (press release) - Thu, 13 Nov 2014 04:56

US FDA Approves Supplemental New Drug Applications for Once-Monthly Long ...
Orthostatic Hypotension and Syncope: INVEGA® SUSTENNA® may induce orthostatic hypotension in some patients due to its alpha-blocking activity. INVEGA® SUSTENNA® should be used with caution in patients with known cardiovascular disease, ... (press release) - Thu, 13 Nov 2014 07:22

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014